Simultaneous response in several domains in patients with psoriatic disease treated with Etanercept as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs
Objective. To evaluate patients with psoriatic arthritis (PsA) receiving etanercept (ETN) monotherapy or ETN plus conventional synthetic disease-modifying antirheumatic drugs (csDMARD) to determine the proportion achieving a clinically meaningful response in arthritis, psoriasis, and quality of life...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
June 1, 2018
|
| In: |
The journal of rheumatology
Year: 2018, Jahrgang: 45, Heft: 6, Pages: 802-810 |
| ISSN: | 1499-2752 |
| DOI: | 10.3899/jrheum.170932 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3899/jrheum.170932 Verlag, lizenzpflichtig, Volltext: http://www.jrheum.org/content/45/6/802 
|
| Verfasserangaben: | Frank Behrens, Lothar Meier, Jörg C. Prinz, Jürgen Jobst, Ralph Lippe, Peter-Andreas Löschmann and Hanns-Martin Lorenz |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 169199989X | ||
| 003 | DE-627 | ||
| 005 | 20220818011218.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200310s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3899/jrheum.170932 |2 doi | |
| 035 | |a (DE-627)169199989X | ||
| 035 | |a (DE-599)KXP169199989X | ||
| 035 | |a (OCoLC)1341309752 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Behrens, Frank |d 1970- |e VerfasserIn |0 (DE-588)128766719 |0 (DE-627)379138840 |0 (DE-576)297322435 |4 aut | |
| 245 | 1 | 0 | |a Simultaneous response in several domains in patients with psoriatic disease treated with Etanercept as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs |c Frank Behrens, Lothar Meier, Jörg C. Prinz, Jürgen Jobst, Ralph Lippe, Peter-Andreas Löschmann and Hanns-Martin Lorenz |
| 264 | 1 | |c June 1, 2018 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.03.2020 | ||
| 520 | |a Objective. To evaluate patients with psoriatic arthritis (PsA) receiving etanercept (ETN) monotherapy or ETN plus conventional synthetic disease-modifying antirheumatic drugs (csDMARD) to determine the proportion achieving a clinically meaningful response in arthritis, psoriasis, and quality of life simultaneously. - Methods. A prospective, multicenter, 52-week observational study in patients with active PsA evaluated treatment with ETN in clinical practice (ClinicalTrials.gov: NCT00293722). This analysis assessed simultaneous achievement of 3 treatment targets: low disease activity (LDA) based on 28-joint count Disease Activity Score (DAS28); body surface area (BSA) involvement ≤ 3%; and a score > 45 on the Medical Outcomes Study Short Form-12 (SF-12) physical component summary. - Results. Of 579 patients, 380 received ETN monotherapy and 199 received combination ETN plus csDMARD. At 52 weeks, data for all 3 disease domains were available for 251 patients receiving monotherapy and 151 receiving combination therapy. In the monotherapy and combination therapy groups, 61 (24.3%) and 37 (24.5%) patients, respectively, achieved all 3 treatment targets simultaneously. A significantly greater proportion of patients receiving monotherapy versus combination therapy achieved SF-12 > 45 (43.0% vs 31.8%; p < 0.05) and DAS28 LDA (72.5% vs 62.3%; p < 0.05). Conversely, BSA ≤ 3% was reached by a significantly greater proportion receiving combination therapy (75.5% vs 56.6%; p < 0.001). However, baseline BSA involvement was higher for the monotherapy group. - Conclusion. While nearly half the patients achieved arthritis and psoriasis treatment targets simultaneously and one-fourth reached all 3 treatment targets, combining ETN and csDMARD did not substantially improve clinical response compared with ETN monotherapy in this real-world PsA patient population. | ||
| 650 | 4 | |a DERMATOLOGY | |
| 650 | 4 | |a ETANERCEPT | |
| 650 | 4 | |a MUSCULOSKELETAL DISEASE | |
| 650 | 4 | |a PSORIATIC ARTHRITIS | |
| 650 | 4 | |a QUALITY OF LIFE | |
| 700 | 1 | |a Lorenz, Hanns-Martin |d 1962- |e VerfasserIn |0 (DE-588)112253865 |0 (DE-627)627277845 |0 (DE-576)167601369 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of rheumatology |d Toronto, Ont. : [Verlag nicht ermittelbar], 2001 |g 45(2018), 6, Seite 802-810 |h Online-Ressource |w (DE-627)325490023 |w (DE-600)2036792-2 |w (DE-576)094529698 |x 1499-2752 |7 nnas |a Simultaneous response in several domains in patients with psoriatic disease treated with Etanercept as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs |
| 773 | 1 | 8 | |g volume:45 |g year:2018 |g number:6 |g pages:802-810 |g extent:9 |a Simultaneous response in several domains in patients with psoriatic disease treated with Etanercept as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs |
| 856 | 4 | 0 | |u https://doi.org/10.3899/jrheum.170932 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://www.jrheum.org/content/45/6/802 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200310 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 112253865 |a Lorenz, Hanns-Martin |m 112253865:Lorenz, Hanns-Martin |d 910000 |d 910100 |e 910000PL112253865 |e 910100PL112253865 |k 0/910000/ |k 1/910000/910100/ |p 7 |y j | ||
| 999 | |a KXP-PPN169199989X |e 3605617867 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"June 1, 2018"}],"id":{"doi":["10.3899/jrheum.170932"],"eki":["169199989X"]},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"given":"Frank","display":"Behrens, Frank","family":"Behrens","role":"aut"},{"role":"aut","given":"Hanns-Martin","family":"Lorenz","display":"Lorenz, Hanns-Martin"}],"title":[{"title":"Simultaneous response in several domains in patients with psoriatic disease treated with Etanercept as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs","title_sort":"Simultaneous response in several domains in patients with psoriatic disease treated with Etanercept as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs"}],"physDesc":[{"extent":"9 S."}],"relHost":[{"pubHistory":["Nachgewiesen 28.2001 -"],"recId":"325490023","note":["Gesehen am 12.03.19"],"disp":"Simultaneous response in several domains in patients with psoriatic disease treated with Etanercept as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugsThe journal of rheumatology","part":{"text":"45(2018), 6, Seite 802-810","pages":"802-810","volume":"45","issue":"6","extent":"9","year":"2018"},"title":[{"title":"The journal of rheumatology","subtitle":"a monthly international peer review journal","title_sort":"journal of rheumatology"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisher":"[Verlag nicht ermittelbar]","dateIssuedKey":"2001","dateIssuedDisp":"2001-","publisherPlace":"Toronto, Ont."}],"id":{"zdb":["2036792-2"],"issn":["1499-2752"],"eki":["325490023"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"]}],"name":{"displayForm":["Frank Behrens, Lothar Meier, Jörg C. Prinz, Jürgen Jobst, Ralph Lippe, Peter-Andreas Löschmann and Hanns-Martin Lorenz"]},"note":["Gesehen am 10.03.2020"],"recId":"169199989X"} | ||
| SRT | |a BEHRENSFRASIMULTANEO1201 | ||